The importation of food, despite occasional problems, doesn't raise the same level of objection that drug importation does. Could part of the reason be that the highly automated food industry remains ahead of the pharmaceutical industry in terms of efficiencies? Blog
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments